Stanford University

Shanghai, China – May 29, 2026 – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that 23 abstracts on NEFECON® (budesonide delayed-release capsules) have been accepted for presentation at the 63rd European Renal Association (ERA) Congress, including 11 oral presentations and 12 e-posters. The congress will take place in Glasgow, United Kingdom, from June 3 to 6, 2026. The newly released results from 21 real-world studies conducted in China further validate the efficacy and safety of NEFECON® in clinical practice and reinforce its position as a cornerstone of first-line treatment for patients with IgA nephropathy. Oral Presentation 01 Title：Real-World Impact of Nefecon Combined with Other lmmunosuppressants in Chinese IgAN Patients Main Author and Institution：Ying Fan, Shuling Chen，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine Time：June 4, 2026，09:39-09:45 BST Location：Focussed Oral Room 5 02 Title：A Real-World Study of Efficacy and Safety of Nefecon in IgA Nephropathy Patients with Different Renal Function Stratifications Main Author and Institution：Ying Yang，The Second Hospital of Shanxi Medical University Time：June 4, 2026，11:33-11:39 BST Location：Focussed Oral Room 2 03 Title：Nefecon as Add-On Therapy in Refractory IgA Nephropathy: A Real-World Case Series Main Author and Institution：Sha Chen, Tianjin Hospital Time：June 4, 2026，16:06-16:12 BST Location：Focussed Oral Room 2 04 Title：Differential Renal Response to Nefecon in IgA Nephropathy: A Retrospective Study Stratified by Baseline eGFR Main Author and Institution：Fanna Liu，The First Affiliated Hospital of Jinan University Time：June 4, 2026，16:54-17:00 BST Location：Focussed Oral Room 3 05 Title：Real-World Analysis of Efficacy and Safety of Nefecon Combined with Low Dose Corticosteroids in High-Risk Progressive IgA Nephropathy Main Author and Institution：Xiaoling Zhou，General Hospital of Ningxia Medical University Time：June 4, 2026，17:21-17:27 BST Location：Focussed Oral Room 7 06 Title：Real-World Study on Efficacy and Safety of Nefecon in IgA Nephropathy Main Author and Institution：Xin Wei，Honghui Zeng，The First Affiliated Hospital of Nanchang University Time：June 4, 2026，09:21-09:27 BST Location：Focussed Oral Room 3 07 Title：Budesonide Combined with Mycophenolate Mofetil Enhances Response Rates in IgA Nephropathy: A Real-World Study Main Author and Institution：Xue Jiang, Hangzhou Traditional Chinese Medicine Hospital Time：June 4, 2026，09:21-09:27 BST Location：Focussed Oral Room 5 08 Title：Podocyte Hypertrophy Predicts Treatment Response to Targeted-Release Budesonide ± Tacrolimus in IgA Nephropathy: A Real-World Retrospective Study Main Author and Institution：Guiqing Tian，Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Time：June 4, 2026，16:06-16:12 BST Location：Focussed Oral Room 3 09 Title：A 15-Month Nefecon Therapy in IgA Nephropathy: A Propensity Score-Matched Study Main Author and Institution：Xiu Yang，The First People's Hospital of Hangzhou Time：June 4, 2026，11:21-11:27 BST Location：Focussed Oral Room 5 10 Title：NefIgArd: Efficacy of Nefecon in Immunoglobulin A Nephropathy Patients With a Baseline Urine Protein-Creatinine Ratio of 0.5 to 1g/gram Main Author and Institution：Jonathan Barratt，University of Leicester Time：June 4, 2026，11:27-11:39 BST Location：Lomond Auditorium 11 Title：NefIgArd: Assessment of Kidney Function With Nefecon Versus Placebo in Patients With Proteinuria or Hematuria Non-Response Main Author and Institution：Richard Lafayette，Stanford University Time：June 4, 2026，11:57-12:09 BST Location：Lomond Auditorium E-Poster 01 Title：Efficacy and Safety of Oral Budesonide Targeted-Release Formulation Combined with Ambrisentan in the Treatment of IgA Nephropathy Main Author and Institution：Weixia Sun，the First Hospital of Jilin University Changchun Location：Research Zone 02 Title：Real-World Study on the Efficacy and Safety of Combination Therapy of Nefecon and Hydroxychloroquine in the Treatment of IgA Nephropathy Main Author and Institution：Xin Wei，The First Affiliated Hospital of Nanchang University Location：Research Zone 03 Title：Efficacy and Safety of Nefecon Combined with Mycophenolate Mofetil in the Treatment of IgA Nephropathy: Real-World Data Main Author and Institution：Xin Wei，The First Affiliated Hospital of Nanchang University Location：Research Zone 04 Title：More treatment options: Real-world efficacy and safety of Nefecon with or without immunosuppression in patients with IgA nephropathy Main Author and Institution：Jing Li，The First Affiliated Hospital of Xinjiang Medical University Location：Research Zone 05 Title：Effectiveness and Safety of Nefecon Beyond Pivotal Trial Populations in IgA Nephropathy: 6-Month Real-World Main Author and Institution：Xingyang Zhao，Tongji Hospital, Huazhong University of Science and Technology Location：Research Zone 06 Title：Comparative Efficacy of Budesonide Enteric-Coated Capsules (Nefecon) in the Management of IgA Nephropathy Stratified by Baseline Proteinuria Levels Main Author and Institution：Jia Lv，The First Affliated Hospital of Xi’an Jiaotong University Location：Research Zone 07 Title：Efficacy of Nefecon in IgA Nephropathy Patients with 24-Hour Urine Protein Excretion of 0.5–1.0 g: A 9-Month Retrospective Study Main Author and Institution：Jun Cheng, The First Affiliated Hospital of Zhejiang University School of Medicine Location：Research Zone 08 Title：Real-World Data on Early Treatment of IgA Nephropathy Patients with Baseline Proteinuria of 0.5-1g/d Using Nefecon for 9 Months Main Author and Institution：Jing Li, First Affiliated Hospital of Xinjiang Medical University Location：Research Zone 09 Title：Impact of Early Diagnosis and Treatment on the Efficacy of Nefecon in Patients with IgA Nephropathy: A Single-Center Follow-Up Study Main Author and Institution：Yi Ren，Longhua Hospital Affiliated to Southern University of Science and Technology Location：Research Zone 10 Title：Early Initiation of Targeted-Release Budesonide in IgA Nephropathy: A Multi-Center Prospective Study Design and Baseline Characteristics Main Author and Institution：Yunlin Feng, Sichuan Provincial People’s Hospital Location：Research Zone 11 Title：Early Initiation of targeted-release budesonide in primary IgA nephropathy: a multicenter prospective study's baseline and interim analysis Main Author and Institution：Yunlin Feng, Sichuan Provincial People’s Hospital Location：Research Zone 12 Title：Beyond Twelve Months: Real-World Efficacy and Safety of Nefecon in Patients With Newly Diagnosed IgA Nephropathy Main Author and Institution：Wenjing Zhang，The First Affiliated Hospital of Xi’an Jiao Tong University Location：Research Zone About NEFECON® NEFECON® is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. NEFECON® was designed as a 4 mg delayed release capsule and is enteric coated so that it would remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer’s patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-IgA1) causing IgA nephropathy. NEFECON® was approved in November 2023 through National Medical Products Administration (NMPA)’s priority review for the treatment of primary IgA nephropathy in adults at risk of disease progression. It was subsequently included in the National Reimbursement Drug List in November 2024, and received full approval from the NMPA in April 2025, irrespective of proteinuria levels, benefiting most individuals living with IgA nephropathy. It has been approved across all Everest Medicines’ territories, including mainland China, Hong Kong SAR, Macau SAR, Taiwan region, China, as well as Singapore and South Korea. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. he Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. References 1.Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870. 2. Zhang H, et al. Kidney360. 2024 Dec 1;5(12):1881-1892. 3.Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886. 4.Edsbäcker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24.

Scientists at Stanford may have uncovered a hidden reason our brains decline with age. Studying the ultra-short-lived turquoise killifish, researchers discovered that the cellular machinery responsible for building proteins begins to jam and malfunction over time. Tiny structures called ribosomes start colliding and stalling while reading genetic instructions, triggering a chain reaction that leads to faulty proteins and harmful clumps linked to diseases like Alzheimer’s.Scientists at Stanford University have uncovered a major clue to why the brain deteriorates with age. Their research points to breakdowns in the cell's protein production system, a process that appears to trigger widespread dysfunction linked to cognitive decline and neurodegenerative diseases such as Alzheimer's. The study, published in Science, focused on how aging disrupts "proteostasis," or protein homeostasis. This system helps cells correctly build, maintain, and dispose of proteins. When proteostasis fails, damaged proteins can accumulate into harmful clumps that interfere with normal brain function. Researchers say the findings provide one of the clearest explanations yet for why aging brains become increasingly vulnerable to disease and mental decline. "We know that many processes become more dysfunctional with aging, but we really don't understand the fundamental molecular principles of why we age," said study author Judith Frydman, the Donald Kennedy Chair in the School of Humanities and Sciences at Stanford. "Our new study begins to provide a mechanistic explanation for a phenomenon widely seen during aging, which is increased aggregation and dysfunction in the processes that make proteins." A Tiny Fish With Big Clues About Aging To investigate what happens in aging brains, the researchers turned to the turquoise killifish, Nothobranchius furzeri. Native to temporary freshwater pools in the African savanna, these brightly colored fish have extremely short lifespans and develop many age-related problems rapidly, making them ideal for aging research. Because mice and other mammals age much more slowly, studying the biological causes of aging can take years. Killifish allow scientists to observe those same processes on a much faster timeline. The team compared young, adult, and old fish, examining many aspects of protein production inside brain cells. They measured amino acid levels, transfer RNA, messenger RNA (mRNA), proteins, and other components involved in cellular protein manufacturing. How Protein Production Starts Breaking Down Proteostasis relies on a careful balance between creating proteins and removing damaged ones. It also helps prevent proteins from folding incorrectly and sticking together in toxic aggregates. These protein clumps are strongly associated with neurodegenerative diseases, including Alzheimer's. Frydman's lab has spent years studying how cells maintain proteostasis in simpler organisms such as yeast and roundworms. The new findings show that similar aging mechanisms also occur in more complex vertebrates like killifish and humans. "With aging, problems mysteriously emerge at many levels -- at the mechanistic, cellular, and organ level -- but one commonality is that all those processes are mediated by proteins," Frydman said. "This study confirms that during aging, the central machinery that makes proteins starts to have quality problems." The researchers traced the issue to a specific phase of protein synthesis known as translation elongation. During this process, ribosomes move along mRNA strands and assemble proteins by adding amino acids one at a time. In older fish brains, the ribosomes frequently stalled or collided with one another. These molecular "traffic jams" reduced the production of healthy proteins and increased protein aggregation. "Our results show that changes in the speed of ribosome movement along the mRNA can have a profound impact on protein homeostasis -- and highlight the essential nature of 'regulated' translation elongation speed of different mRNAs in the context of aging," said Jae Ho Lee, co-lead author of the paper who worked on this as a postdoctoral scholar in the Frydman lab. He is now an assistant professor at Stony Brook University. Solving Another Aging Mystery The discovery may also help explain another puzzling hallmark of aging called "protein-transcript decoupling." In aging organisms, changes in mRNA levels often stop matching changes in protein levels, even though mRNA carries the instructions needed to build proteins. The Stanford team found that aging-related disruptions in protein synthesis, particularly involving ribosomes, can explain why this disconnect occurs. Many of the proteins affected by these failures are involved in maintaining genome stability and cellular integrity. As those systems weaken, broader aging-related dysfunction can follow. "Showing that the process of protein production loses fidelity with aging provides a kind of underlying rationale for why all these other processes start to malfunction with age," said Frydman. "And, of course, the key to solving a problem is to understand why it's gone wrong. Otherwise, you're just fumbling in the dark." Potential New Targets for Alzheimer's and Cognitive Decline The researchers now plan to investigate whether ribosome dysfunction directly contributes to human neurodegenerative diseases and whether therapies aimed at improving protein production could help protect the aging brain. They are especially interested in exploring whether boosting translation efficiency or improving ribosome quality control could restore healthier protein balance in brain cells and potentially slow cognitive decline. "This work provides new insights on protein biogenesis, function, and homeostasis in general, as well as a new potential target for intervention for aging-associated diseases," said Lee. The team is also studying how these molecular processes influence longevity and cognitive aging across multiple species. Frydman, a professor of biology in the School of Humanities and Sciences and of genetics in the School of Medicine, is also a member of Stanford Bio-X, the Stanford Cancer Institute, and the Wu Tsai Neurosciences Institute, and a faculty fellow of Sarafan ChEM-H. Frydman is also co-director of the Paul F. Glenn Center for Biology of Aging Research at Stanford. Additional work on the mechanisms of human neuronal aging and its link to Alzheimer's Disease in the Frydman lab is funded by the Knight Initiative for Brain Resilience.

CASTRO VALLEY, Calif., May 28, 2026 /PRNewswire/ -- Dr. Deryk G. Jones is a highly respected orthopedic surgeon and sports medicine specialist, renowned for his expertise in biologic reconstructive surgery restoring damaged articular cartilage, ligaments, menisci and alignment in the knee, hip, shoulder, elbow and ankle. He served as Section Head of Sports Medicine and Cartilage Restoration at the Ochsner Andrews Sports Medicine Institute for 21 years. During his 28 year career, Dr. Jones has been at the forefront of innovation exploring numerous nonoperative and operative treatments, including FDA trials utilizing stem cells, umbilical injections, autologous chondrocytes and synthetic meniscus replacement to name a few. Continue Reading Deryk G. Jones Currently, he is the Chair of the Orthopedic and Sports Medicine Service Line for Sutter Health; he is focused on the development of Advanced Complex Centers of Excellence in the six divisions within Sutter Health's expansive California based geography. Dr. Jones' educational foundation is extensive, having earned a double major in Biology and Philosophy from Emory University, followed by his Doctor of Medicine from Stanford University School of Medicine. He completed a general surgical internship at Brigham and Women's Hospital in Boston and an orthopedic surgical residency at the Harvard Combined Orthopedic Program. Further refining his expertise, he pursued a fellowship in sports medicine and shoulder surgery at the University of Pittsburgh Medical Center (UPMC). He is board-certified in sports medicine and orthopedic surgery. A leader in meniscal transplantation, autologous chondrocyte implantation, minimally invasive joint replacements, and arthroscopic-assisted ligament and fracture repair, Dr. Jones is deeply involved in cutting-edge research and advancements in the field. His affiliations include the American Orthopedic Sports Medicine Society, Arthroscopy Association of North America, the International Sports Medicine and Orthopedic Arthroscopy Medical Association, and the American Academy of Orthopedic Surgeons. He is also a Fellow of the American Orthopedic Association. Dr. Jones serves as a full professor of orthopedic surgery at the University of Queensland, Australia (Ochsner Clinical School), where he is dedicated to research as well as mentoring and educating the next generation of orthopedic professionals. Beyond medicine, Dr. Jones is a committed member of the Baha'i Faith and cherishes his role as a husband to Tina, with whom he has been married for 26 years, and father to their four children Meshya, Cameryn, Deryk Jr. and James. Looking ahead, Dr. Jones is committed to expanding the role of biologic reconstructive techniques and regenerative medicine in orthopedics and sports medicine, ensuring that patients receive the most advanced, minimally invasive treatments available. His mission is to continue bridging the gap between cutting-edge research and real-world patient care, improving outcomes and recovery times for athletes and active individuals alike. In addition to his administrative duties as Chair of Orthopedic and Sports Medicine at Sutter Health he will continue treating patients focusing on Biologic Reconstructive arthroscopic and minimally invasive procedures. He joined the prestigious East Bay Medical Group in December 2025 and his practice address will be: 20101 Lake Chabot Road MOB 4th Floor, Castro Valley, CA 94546. Patients can also visit his personal website at derykjonesmd.com. Contact: Katherine Green 516-825-5634 [email protected] SOURCE The Inner Circle 21% more press release views with Request a Demo